AMSTERDAM, the Netherlands, July 7, 2016 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced the appointment of Jonathan Garen as Chief Business Officer. Mr. Garen has more than 20 years of experience in business development within the pharmaceutical sector, having previously held senior positions at Actavis plc, Forest Laboratories, Inc. and Pharmacia Corporation. Mr. Garen will be responsible for strategic transactions at uniQure, with a focus on business development and alliance management. Mr. Garen will report to Daniel Soland, Chief Executive Officer of uniQure, and will be based in the Company's Lexington, Massachusetts facility.
"Jon has an accomplished track record in driving business development initiatives and executing value-generating strategic transactions," said Mr. Soland. "Collaborations, licenses and other corporate development initiatives are a vital part of our growth strategy at uniQure, and Jon's vast experience will be instrumental as we further develop and execute our corporate strategy."
"I am very pleased to be joining uniQure at this important time for the company," stated Jonathan Garen. "There are tremendous opportunities ahead as we further advance our gene therapy clinical programs and research pipeline, and I look forward to working with Dan and the leadership team to maximize our strategic opportunities."
Mr. Garen was most recently with Syros Pharmaceuticals, Inc., a venture-backed company developing medicines that control genes, where he served as Chief Business Officer. Prior to joining Syros, he was Assistant Vice President, Business Development at Forest Laboratories, Inc. from 2003 to 2014, and subsequently held the same position at Actavis plc following its acquisition of Forest Laboratories. Earlier in his career, Mr. Garen was Director of Global Licensing with Pharmacia Corporation and a Founder and Vice President of Technology Exchange, Inc.
Mr. Garen holds a Master of Environmental Science degree from Yale University and a Bachelor of Science degree in Physics from Massachusetts Institute of Technology.
uniQure is delivering on the promise of gene therapy - single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with CNS, liver/metabolic and cardiovascular diseases. www.uniQure.com
uniQure Forward-Looking Statement
This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to", "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. These forward-looking statements include, but are not limited to, statements regarding the development of our gene therapy product candidates, the success of our collaborations and the risk of cessation, delay or lack of success of any of our ongoing or planned clinical studies and/or development of our product candidates. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, risks associated with collaboration arrangements, our and our collaborators' clinical development activities, regulatory oversight, product commercialization and intellectual property claims, as well as the risks, uncertainties and other factors described under the heading "Risk Factors" in uniQure's 2015 Annual Report on Form 20-F filed with the Securities and Exchange Commission on April 4, 2016. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future.
Maria E. Cantor
Direct: +1 339 970 7536
PDF version of release http://hugin.info/157414/R/2026285/753197.pdf